Catheterization Lab Equipment in Georgia

Cydar Medical develops cloud-based AI-driven surgical navigation and planning software for minimally invasive, image-guided procedures. The company's core platform, CYDAR MAPS, comprises three integrated modules: Plan (3D surgical planning with AI-enhanced vessel measurements), Guide (intraoperative surgical guidance software with real-time visualization), and Analyze (automatic volume assessment for aortic and other anatomical measurements from CT scans). The platform also features Collaborate functionality enabling remote sharing of imaging data and live surgical streaming across multidisciplinary teams. Primary clinical applications focus on complex vascular and endovascular interventions, including EVAR (endovascular aortic repair) and branch vessel cannulation. Key benefits documented include reduction in radiation exposure, procedure time, and contrast agent use. The platform is designed for enterprise integration into existing hospital systems and operating room workflows. Cydar emphasizes data security, compliance, and 24/7 clinical support via the Cydar Companion App and integrated expert consultation. The company serves hospitals, health systems, and specialty surgical centers across the US and Europe. Regulatory certifications include FDA 510(k) clearance and adherence to international standards (ISO 13485, SOC 2 compliance visible on site). Cydar operates a cloud-based infrastructure supporting massive volumes of 3D imaging data to continuously improve AI algorithms and clinical outcomes.

Fehling Surgical Instruments, Inc. is a manufacturer of specialized surgical instruments focused on cardiac, thoracic, vascular, and neurological surgery. The company designs and produces precision surgical instruments including retractors, rongeurs, and innovative devices for minimally invasive cardiac procedures. Their product portfolio includes the Atrial Blade, a self-contained retractor for minimally invasive mitral valve repair offering precise manipulation of height, rotation, and angle for optimal surgical access. The company also manufactures Kerrisons and pituitary rongeurs, which have received FDA 510(k) certification. Fehling Surgical develops simulation systems and training platforms for surgical education, with their mitral valve retractor simulator specifically recommended by cardiac surgeons for simulation-based training in minimally invasive mitral valve surgery (MIMVS). The company serves cardiac surgeons, thoracic surgeons, neurosurgeons, and vascular surgeons globally, participating in major professional conferences including AATS, ISMICS, STS, CNS, and EACTS. They maintain regulatory compliance with FDA 510(k) clearances and operate with quality standards appropriate for surgical instrument manufacturing. Fehling Surgical maintains an international presence with operations in both the United States and Germany.

Artivion is a specialized cardiovascular medical device company focused exclusively on aortic and cardiac surgery solutions. The company manufactures and markets a comprehensive portfolio of devices for treating aortic diseases, aortic dissections, and cardiac valve disorders. Product lines include mechanical and biological heart valves (ON-X Aortic and Mitral Valves, CRYOVALVE allografts), aortic arch solutions (AMDS Hybrid Prosthesis, E-VITA OPEN NEO, NEXUS stent graft systems), thoracoabdominal and abdominal aortic stent grafts (E-TEGRA, E-LIAC, E-NSIDE TAAA), peripheral aortic devices, and ancillary surgical solutions including BIOGLUE surgical adhesive and decellularized pericardium (PHOTOFIX). Artivion recently acquired Ascyrus Medical in 2020, expanding its aortic arch offerings. The AMDS Hybrid Prosthesis, developed for acute DeBakey Type I aortic dissections, received FDA Humanitarian Device Exemption (HDE) in December 2024 and is supported by the PERSEVERE pivotal clinical trial. Products are regulated through FDA 510(k) clearances and PMA pathways, with multiple investigational device exemptions (IDEs) active. The company collaborates with cardiac and vascular surgeons worldwide and supports clinical evidence generation through real-world post-market studies and pivotal trials. Artivion serves hospitals, surgical centers, and cardiac/vascular surgery programs globally, with particular emphasis on advanced aortic interventions and valve replacement technologies.

MiRus is a medical device company developing proprietary implants and procedural solutions leveraging its proprietary Molybdenum-Rhenium (MoRe®) alloy technology. The company focuses on cardiovascular and orthopedic applications with an integrated platform spanning pre-operative, intra-operative, and post-operative solutions. MiRus' core technology, MoRe®, represents over 15 years of R&D and offers advantages over traditional medical materials (titanium, cobalt chromium) including smaller implant profiles, improved durability, enhanced biocompatibility, and significantly lower metal ion release. The company's cardiovascular portfolio includes the Siegel™ Transcatheter Aortic Valve (TAVR) system, currently in the STAR randomized controlled trial for symptomatic severe aortic stenosis. The orthopedic portfolio includes the IO™ Expandable Wedge Osteotomy System (FDA 510(k) cleared February 2026) and the EUROPA™ Posterior Cervical Fusion System (recipient of FDA New Technology Add-on Payment, NTAP). MiRus is headquartered in Marietta, Georgia, and was founded by experienced entrepreneurs with a track record of developing disruptive medical technologies. The company maintains an active clinical development program with multi-center trials and regulatory engagement with the FDA.